Semaglutide improves health-related quality of life vs placebo when added to standard-of care in patients with type 2 diabetes at high risk (SUSTAIN 6)

Simple item page
dc.contributor.authorJódar Gimeno, José Esteban
dc.contributor.authorPolonsky, William
dc.contributor.authorRéa, Rosangela
dc.contributor.authorWarren, Mark
dc.contributor.authorVilsbøll, Tina
dc.contributor.authorHakan Bloch, J.
dc.contributor.authorVrazic, H.
dc.contributor.authorLindeberg, Staffan
dc.contributor.authorBain, Stephen
dc.date.accessioned2021-05-06T17:35:45Z
dc.date.available2021-05-06T17:35:45Z
dc.date.issued2018
dc.description.filiationUEMspa
dc.description.impact7.113 JCR (2018) Q1, 12/145 Endocrinology & Metabolismspa
dc.description.impact3.000 SJR (2018) Q1, 9/245 Endocrinology, Diabetes and Metabolismspa
dc.description.impactNo data IDR 2018spa
dc.description.sponsorshipSin financiaciónspa
dc.identifier.citationJodar, E., Polonsky, W., Rea, R., Warren, M., Vilsboll, T., Hakan-Bloch, J., Vrazic, H., Lindberg, S., & Bain, S. C. (2018). Semaglutide improves health-related quality of life vs placebo when added to standard-of care in patients with type 2 diabetes at high risk (SUSTAIN 6). Diabetologia, 61(S1), S372-S373.spa
dc.identifier.issn0012-186X
dc.identifier.issn1432-0428
dc.identifier.urihttp://hdl.handle.net/11268/10013
dc.language.isoengspa
dc.peerreviewedSispa
dc.rights.accessRightsrestricted accessspa
dc.subject.otherDiabetes mellitus tipo 2spa
dc.subject.otherCalidad de vidaspa
dc.subject.unescoMedicina preventivaspa
dc.subject.unescoEnfermedad cardiovascularspa
dc.titleSemaglutide improves health-related quality of life vs placebo when added to standard-of care in patients with type 2 diabetes at high risk (SUSTAIN 6)spa
dc.typeconference outputspa
dspace.entity.typePublication
relation.isAuthorOfPublication3b2bb27c-56d4-4094-87ab-73ae34ec6089
relation.isAuthorOfPublication.latestForDiscovery3b2bb27c-56d4-4094-87ab-73ae34ec6089

Files

Collections

Otras Áreas de Investigación de Salud